It was reported at a national conference of spine surgeons Thursday, November
3rd that there is an increased cancer risk with a certain bone medication.
Infuse, a Medtronicproduct, was discovered to increase patient cancer
risks when used in high doses during spinal fusion procedures. An analysis
led by a Stanford University orthopedic surgeon found that cancer was
three to five times more likely to develop in spine surgery patients who
received a
bone
growth stimulating agent as a part of their clinical trial. The cancer
was found typically within two to three years after the product was implanted.
